Abstract

Venous thromboembolism (VTE) is a common complication in ambulatory cancer patients receiving chemotherapy. Current clinical guidelines recommend against the use of routine primary thromboprophylaxis in unselected ambulatory cancer patients. The Khorana score is a risk assessment tool derived and prospectively validated for the identification of cancer patients at high risk of thrombotic complications. Recently, 2 randomized, controlled trials have assessed the use of low-dose direct oral Xa inhibitors, apixaban and rivaroxaban, for the prevention of cancer-associated thrombosis in ambulatory patients at intermediate to high risk of VTE (Khorana score ≥2). Taken together, these trials have shown that low-dose direct oral Xa inhibitors reduce the risk of VTE in this patient population without a significant increase in major bleeding. These results should encourage clinicians to consider the use of primary thromboprophylaxis in ambulatory cancer patients at intermediate to high risk of VTE who do not have any apparent risk factors for bleeding. The direct oral Xa inhibitors have also been assessed in the acute management of cancer-associated thrombosis. Current evidence suggests that these drugs are a convenient, effective, and safe option for the management of acute VTE in many cancer patients. Low-molecular weight heparin, however, may continue to be the treatment of choice depending on the presence of bleeding risk factors, the type of cancer, drug-drug interactions, and patient preferences.

References

References
1.
Timp
JF
,
Braekkan
SK
,
Versteeg
HH
,
Cannegieter
SC
.
Epidemiology of cancer-associated venous thrombosis
.
Blood
.
2013
;
122
(
10
):
1712
-
1723
.
2.
Heit
JA
,
Silverstein
MD
,
Mohr
DN
,
Petterson
TM
,
O’Fallon
WM
,
Melton
LJ
3rd
.
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study
.
Arch Intern Med
.
2000
;
160
(
6
):
809
-
815
.
3.
Cohen
AT
,
Katholing
A
,
Rietbrock
S
,
Bamber
L
,
Martinez
C
.
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study
.
Thromb Haemost
.
2017
;
117
(
1
):
57
-
65
.
4.
Khorana
AA
,
Francis
CW
,
Culakova
E
,
Kuderer
NM
,
Lyman
GH
.
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
.
J Thromb Haemost
.
2007
;
5
(
3
):
632
-
634
.
5.
Khorana
AA
.
Venous thromboembolism and prognosis in cancer
.
Thromb Res
.
2010
;
125
(
6
):
490
-
493
.
6.
Lyman
GH
,
Bohlke
K
,
Khorana
AA
, et al
;
American Society of Clinical Oncology
.
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014
.
J Clin Oncol
.
2015
;
33
(
6
):
654
-
656
.
7.
Mandalà
M
,
Falanga
A
,
Roila
F
;
ESMO Guidelines Working Group
.
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
.
Ann Oncol
.
2011
;
22
(
suppl 6
):
vi85
-
vi92
.
8.
Agnelli
G
,
Gussoni
G
,
Bianchini
C
, et al
;
PROTECHT Investigators
.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
.
Lancet Oncol
.
2009
;
10
(
10
):
943
-
949
.
9.
Agnelli
G
,
George
DJ
,
Kakkar
AK
, et al
;
SAVE-ONCO Investigators
.
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer
.
N Engl J Med
.
2012
;
366
(
7
):
601
-
609
.
10.
Altinbas
M
,
Coskun
HS
,
Er
O
, et al
.
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
.
J Thromb Haemost
.
2004
;
2
(
8
):
1266
-
1271
.
11.
Elit
LM
,
Lee
AY
,
Parpia
S
, et al
.
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study
.
Thromb Res
.
2012
;
130
(
6
):
894
-
900
.
12.
Haas
SK
,
Freund
M
,
Heigener
D
, et al
;
TOPIC Investigators
.
Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer
.
Clin Appl Thromb Hemost
.
2012
;
18
(
2
):
159
-
165
.
13.
Khorana
AA
,
Francis
CW
,
Kuderer
NM
, et al
.
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial
.
Thromb Res
.
2017
;
151
:
89
-
95
.
14.
Lecumberri
R
,
López Vivanco
G
,
Font
A
, et al
.
Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study
.
Thromb Res
.
2013
;
132
(
6
):
666
-
670
.
15.
Macbeth
F
,
Noble
S
,
Evans
J
, et al
.
Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial
.
J Clin Oncol
.
2016
;
34
(
5
):
488
-
494
.
16.
Perry
JR
,
Julian
JA
,
Laperriere
NJ
, et al
.
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
.
J Thromb Haemost
.
2010
;
8
(
9
):
1959
-
1965
.
17.
van Doormaal
FF
,
Di Nisio
M
,
Otten
HM
,
Richel
DJ
,
Prins
M
,
Buller
HR
.
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer
.
J Clin Oncol
.
2011
;
29
(
15
):
2071
-
2076
.
18.
Di Nisio
M
,
Porreca
E
,
Candeloro
M
,
De Tursi
M
,
Russi
I
,
Rutjes
AW
.
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
.
Cochrane Database Syst Rev
.
2016
;
12
:
CD008500
.
19.
Ay
C
,
Pabinger
I
,
Cohen
AT
.
Cancer-associated venous thromboembolism: burden, mechanisms, and management
.
Thromb Haemost
.
2017
;
117
(
2
):
219
-
230
.
20.
Lyman
GH
,
Khorana
AA
,
Kuderer
NM
, et al
;
American Society of Clinical Oncology Clinical Practice
.
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update
.
J Clin Oncol
.
2013
;
31
(
17
):
2189
-
2204
.
21.
Khorana
AA
,
Kuderer
NM
,
Culakova
E
,
Lyman
GH
,
Francis
CW
.
Development and validation of a predictive model for chemotherapy-associated thrombosis
.
Blood
.
2008
;
111
(
10
):
4902
-
4907
.
22.
Ay
C
,
Dunkler
D
,
Marosi
C
, et al
.
Prediction of venous thromboembolism in cancer patients
.
Blood
.
2010
;
116
(
24
):
5377
-
5382
.
23.
Lustig
DB
,
Rodriguez
R
,
Wells
PS
.
Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis
.
Thromb Res
.
2015
;
136
(
6
):
1099
-
1102
.
24.
Khorana
AA
,
Francis
CW
.
Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future
.
Thromb Res
.
2018
;
164
(
suppl 1
):
S70
-
S76
.
25.
Khorana
AA
,
Soff
GA
,
Kakkar
AK
, et al
;
CASSINI Investigators
.
Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer
.
N Engl J Med
.
2019
;
380
(
8
):
720
-
728
.
26.
Schulman
S
,
Kearon
C
;
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
.
J Thromb Haemost
.
2005
;
3
(
4
):
692
-
694
.
27.
Carrier
M
,
Abou-Nassar
K
,
Mallick
R
, et al
;
AVERT Investigators
.
Apixaban to prevent venous thromboembolism in patients with cancer
.
N Engl J Med
.
2019
;
380
(
8
):
711
-
719
.
28.
Agnelli
G
.
Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer
.
N Engl J Med
.
2019
;
380
(
8
):
781
-
783
.
29.
Mulder
FI
,
Candeloro
M
,
Kamphuisen
PW
, et al
;
CAT-prediction collaborators
.
The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis
.
Haematologica
.
2019
;
104
(
6
):
1277
-
1287
.
30.
Blix
K
,
Gran
OV
,
Severinsen
MT
, et al
.
Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort
.
J Thromb Haemost
.
2018
;
16
(
7
):
1327
-
1335
.
31.
Font
C
,
Farrús
B
,
Vidal
L
, et al
.
Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients
.
Ann Oncol
.
2011
;
22
(
9
):
2101
-
2106
.
32.
den Exter
PL
,
Hooijer
J
,
Dekkers
OM
,
Huisman
MV
.
Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients
.
J Clin Oncol
.
2011
;
29
(
17
):
2405
-
2409
.
33.
den Exter
PL
,
Kroft
LJ
,
van der Hulle
T
,
Klok
FA
,
Jiménez
D
,
Huisman
MV
.
Embolic burden of incidental pulmonary embolism diagnosed on routinely performed contrast-enhanced computed tomography imaging in cancer patients
.
J Thromb Haemost
.
2013
;
11
(
8
):
1620
-
1622
.
34.
van der Hulle
T
,
den Exter
PL
,
Planquette
B
, et al
.
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients
.
J Thromb Haemost
.
2016
;
14
(
1
):
105
-
113
.
35.
O’Connell
C
,
Razavi
P
,
Ghalichi
M
, et al
.
Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning
.
J Thromb Haemost
.
2011
;
9
(
2
):
305
-
311
.
36.
Di Nisio
M
,
Carrier
M
.
Incidental venous thromboembolism: is anticoagulation indicated?
Hematology Am Soc Hematol Educ Program
.
2017
;
2017
(
1
):
121
-
127
.
37.
Kunapareddy
G
,
Switzer
B
,
Jain
P
, et al
.
Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting
.
Res Pract Thromb Haemost
.
2019
;
3
(
2
):
226
-
233
.
38.
Noble
S
,
Matzdorff
A
,
Maraveyas
A
,
Holm
MV
,
Pisa
G
.
Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology
.
Haematologica
.
2015
;
100
(
11
):
1486
-
1492
.
39.
Vazquez
SR
.
Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions
.
Blood
.
2018
;
132
(
21
):
2230
-
2239
.
40.
Kearon
C
,
Akl
EA
,
Ornelas
J
, et al
.
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016;150(4):988]
.
Chest
.
2016
;
149
(
2
):
315
-
352
.
41.
Farge
D
,
Bounameaux
H
,
Brenner
B
, et al
.
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
.
Lancet Oncol
.
2016
;
17
(
10
):
e452
-
e466
.
42.
Kahale
LA
,
Hakoum
MB
,
Tsolakian
IG
, et al
.
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer
.
Cochrane Database Syst Rev
.
2018
;
6
:
CD006650
.
43.
Raskob
GE
,
van Es
N
,
Verhamme
P
, et al
;
Hokusai VTE Cancer Investigators
.
Edoxaban for the treatment of cancer-associated venous thromboembolism
.
N Engl J Med
.
2018
;
378
(
7
):
615
-
624
.
44.
Young
AM
,
Marshall
A
,
Thirlwall
J
, et al
.
Comparison of an Oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)
.
J Clin Oncol
.
2018
;
36
(
20
):
2017
-
2023
.
45.
McBane
RD
,
Wysokinski
WE
,
Le-Rademacher
J
, et al
. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE Trial. Presentation at Blood. 2 December 2018. San Diego, CA.
46.
Carrier
M
,
Blais
N
,
Crowther
M
, et al
.
Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus
.
Curr Oncol
.
2018
;
25
(
5
):
329
-
337
.
You do not currently have access to this content.